Skip to main content
In stock|Hormonal Therapy

Rintodestrant

Oncology TypeSolid Tumour (Breast)
Drug Class / MechanismSelective Estrogen Receptor Degrader (SERD)
No Image
Description

Rintodestrant is classified as a Selective Estrogen Receptor Degrader (SERD), sourced for use within our Hormonal Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryHormonal Therapy
Oncology TypeSolid Tumour (Breast)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3